Arformoterol

Arformoterol
Clinical data
Trade names Brovana
AHFS/Drugs.com Monograph
MedlinePlus a602023
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Inhalation solution for nebuliser
ATC code none
Legal status
Legal status
Pharmacokinetic data
Protein binding 52–65%
Biological half-life 26 hours
Identifiers
CAS Number 67346-49-0 YesY
PubChem (CID) 3083544
IUPHAR/BPS 7479
DrugBank DB01274 YesY
ChemSpider 2340731 YesY
UNII F91H02EBWT YesY
ChEBI CHEBI:408174 YesY
ChEMBL CHEMBL1201137 N
Chemical and physical data
Formula C19H24N2O4
Molar mass 344.405 g/mol
 NYesY (what is this?)  (verify)

Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]

It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

  1. ↑ "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.

External links

This article is issued from Wikipedia - version of the 9/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.